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There was an error in the description of GLORIA-AF registry program at page 10 in this 
Supplement by Casolo et al. [Farmeconomia. Health economics and therapeutic pathways 
2019; 20(Suppl 1): 3-16; https://doi.org/10.7175/fe.v20i1S.1454]. The online version has 
been corrected on February 12, 2020, as shown below.
The paragraph «GLORIA-AF is a prospective registry program describing antithrombotic 
treatment patterns in patients with newly diagnosed NVAF at risk of stroke. The study of 
Huisman et al. [21] aimed at describing data of phase 2, which began when the first NOAC 
(dabigatran) became available and comparing them with data of phase 1 (pre-NOAC era). 
Phase 1 involved 1,063 patients, of whom 32.8% received VKA, 41.7% acetylsalicylic acid, 
and 20.2% did not receive any antithrombotic therapy. In phase 2 (n = 15,092), the prescrip-
tion of oral anticoagulant drugs has increased (79.9% of patients, of whom 47.6% received 
NOAC and 32.3% VKA) while 7.9% of patients remain undertreated. Europe-related data 
(Figure 3) confirm the improvement of anticoagulation therapy (64.1% in phase 1 vs 89.8% in 
phase 2): particularly in phase 2, treatment with NOAC was more common than VKA (52.3% 
and 37.8%, respectively).» has been replaced by «GLORIA-AF is a prospective registry pro-
gram describing antithrombotic treatment patterns in patients with newly diagnosed NVAF at 
risk of stroke. It comprises three phases: phase 1, before the introduction of NOACs; phase 2, 
during the time of the introduction of dabigatran, the first NOAC; and phase 3, once NOACs 
have been established in clinical practice (still ongoing). Phase 1 involved 1,063 patients, 
of whom 32.8% received VKA, 41.7% acetylsalicylic acid, and 20.2% did not receive any 
antithrombotic therapy. The phase 2 aim was to describe the effectiveness and safety of dabi-
gatran etexilate over 2 years from routine clinical practice in GLORIA-AF patients who are 
newly diagnosed with NVAF and at risk of stroke. In phase 2 (n = 15,092), the prescription of 
oral anticoagulant drugs has increased (79.9% of patients, of whom 47.6% received NOAC 
and 32.3% VKA) while 7.9% of patients remain undertreated. Europe-related data (Figure 3) 
confirm the improvement of anticoagulation therapy (64.1% in phase 1 vs 89.8% in phase 2): 
particularly in phase 2, treatment with NOAC was more common than VKA (52.3% and 
37.8%, respectively)».
We apologize for any inconvenience caused.
